---
title: Stable Ischemic Disease
author: J. Austin Straley, DO
date: 2024-03-16
updated: 2024-04-25
categories:
  - Cardiology
---
## Management

* [4S: Statins reduce Death, MI, Revasc in Angina/MI patients](https://pubmed.ncbi.nlm.nih.gov/7968073/){:target="_blank"}
* [SATURN: Crestor better LDL reduction, no better mortality than Lipitor](https://pubmed.ncbi.nlm.nih.gov/22085316/){:target="_blank"}
    * Atorvastatin (Lipitor)
        * [Muscle toxicity w/concurrent Amiodarone use (0.7%)](https://pubmed.ncbi.nlm.nih.gov/15860984/){:target="_blank"}
    * Rosuvastatin (Crestor)
        * [Crestor FDA (Renal Dosing)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021366s040s041lbl.pdf){:target="_blank"}
        * [Crestor to prevent vascular events in patients with elevated CRP](https://pubmed.ncbi.nlm.nih.gov/18997196/){:target="_blank"}
    * Side Effects
        * [Statin induced diabetes and its clinical implications](https://pubmed.ncbi.nlm.nih.gov/25210397/){:target="_blank"}
        * [Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis](https://pubmed.ncbi.nlm.nih.gov/21693744/){:target="_blank"}
        * [Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials](https://pubmed.ncbi.nlm.nih.gov/20167359/){:target="_blank"}
        * [Statin-Associated Myopathy](https://pubmed.ncbi.nlm.nih.gov/12672737/){:target="_blank"}
            * [Adverse events with concomitant amiodarone and statin therapy](https://pubmed.ncbi.nlm.nih.gov/15860984/){:target="_blank"}
        * [Asymptomatic hypothyroidism and statin-induced myopathy](https://pubmed.ncbi.nlm.nih.gov/17872677/){:target="_blank"}
* [COURAGE: PCI w/BMS in Stable CAD non-superior to medical therapy](https://pubmed.ncbi.nlm.nih.gov/17387127/){:target="_blank"}
* [In life expectancy <1, discontinuation of statin did not increase 60-day mortality](https://pubmed.ncbi.nlm.nih.gov/20818875/){:target="_blank"}

![Courtesy of Riordan M, Schuetze K.](/assets/images/im-guide/cards/stable-ischemic-disease/Vascular-EA-Schuetze-Riordan-Fig1.webp)

## Revascularization (CABG)

* [SYNTAX: Less CV events at 1 year w/CABG vs. PCI in 3-vessel and/or LM disease][3]
    * 17.8% vs. 12.4%; driven by need for repeat revascularization in PCI group
    * Use of only paclitaxel stents, which have higher rate of angiographic restenosis than either the sirolimus- or everolimus-eluting stents
    * [Five-year outcomes][4]
        * Roughly equivalent unless high Syntax score which favors surgery
* [Syntax Score][5]
    * The SYNTAX score is a grading system that evaluates the complexity and prognosis of patients undergoing percutaneous coronary intervention (PCI)
    * [Calculator][6]
* [Indications for CABG][1]
    * Class 1
        * LM w/complex CAD
        * LM w/Syntax score >33
        * LM w/complex CAD + Syntax score >33 + Suitable Candidate
        * MVCAD w/suitable anatomy + Suitable Candidate + LVEF $\leq$ 35%
    * Class 2a
        * MVCAD w/suitable anatomy + Suitable Candidate + LVEF $\gt$ 35%
            * ISCHEMIA[^1], FAME 2[^2], and 10-year updates from the MASS II trial showing a reduction in CV mortality[^3]
    * Class 2b
    * MVCAD w/suitable anatomy + LVEF >50% (Note PCI also 2b)
    * IMA (internal mammary artery) remains preferred choice for LAD
        * Radial preferred over SVG for 2nd most important vessel (non-LAD)
            * AATS disagrees with this without patient specifiers*

## Post-CABG Management

* ~10-20% readmitted within 30 days
* [Consider the 3 "I"s][2]
    * Infectious
        * [Sternal wounds][7]
    * Inflammatory
        * Pericarditis
            * Get TTE, contact primary surgeon
            * May lead to Tamponade
                * Commonly presents early (<7 days)
    * Ischemic
        * Myocardial Infarction
* Dyspnea is common post-operatively
    * Once discharged, new-onset dyspnea should be evaluated for (Most to Least likely):
        * Pleural effusion (50%), atelectasis, congestive heart failure (13%), pneumonia (2.4%) and pulmonary embolism[^4]
* 30% develop Atrial Fibrillation
    * Usually self-limiting if new-onset
    * Return to NSR by 6-12 weeks out
* 30% AKI
* 50-70% develop cognitive dysfunction
* Delirium in 73%

[^1]: https://www.nejm.org/doi/full/10.1056/NEJMoa1915922
[^2]: https://pubmed.ncbi.nlm.nih.gov/20733102/
[^3]: https://pubmed.ncbi.nlm.nih.gov/25176289/
[^4]: https://www.cmaj.ca/content/193/19/E689/tab-related-content/

[1]: https://www.acc.org/Latest-in-Cardiology/Articles/2022/10/31/13/02/Key-Takeaways-From-the-2021-Coronary-Revascularization-Guidelines{:target="_blank"}
[2]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157999/{:target="_blank"}
[3]: https://www.wikijournalclub.org/wiki/SYNTAX{:target="_blank"}
[4]: https://pubmed.ncbi.nlm.nih.gov/24700706/{:target="_blank"}
[5]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348991/{:target="_blank"}
[6]: https://syntaxscore.org/calculator/start.htm/{:target="_blank"}
[7]: https://www.cmaj.ca/content/cmaj/suppl/2021/05/04/193.19.E689.DC1/191108-view-2-at.pdf{:target="_blank"}
